News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Actelion Ltd. Swings to Profit, Key Drug Tracleer Disappoints
April 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, April 22 (Reuters) - Swiss biotech company Actelion Ltd swung to a first-quarter net profit of 48 million Swiss francs ($47.43 million), but results were hit by the weak dollar and sales of key drug Tracleer disappointed.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
C-suite
Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home
February 25, 2026
·
2 min read
·
Annalee Armstrong
Weight loss
Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B
February 25, 2026
·
2 min read
·
Tristan Manalac
Startups
Harbour Cofunds Cancer Startup, Hands Off Clinical-Stage Antibody
February 25, 2026
·
2 min read
·
Tristan Manalac
Funding
Slate, Alveus Raise Hefty Series A Hauls for Migraine, Obesity Drugs
February 25, 2026
·
2 min read
·
Tristan Manalac
